Prostate Cancer - Results from #2960

Impact of an NCCN-Compliant Multidisciplinary Conference on Treatment Decisions for Localized Prostate Cancer. April 6, 2023

Current Status and Future Direction to Address Disparities in Diversity, Equity, and Inclusion in Prostate Cancer Care. April 5, 2023

Salvage Stereotactic Reirradiation for Local Recurrence in the Prostatic Bed After Prostatectomy: A Retrospective Multicenter Study. April 5, 2023

Adherence to oral hormonal therapy in advanced prostate cancer: a scoping review. April 5, 2023

Unanswered questions in prostate cancer - findings of an international multi-stakeholder consensus by the PIONEER consortium. April 5, 2023

Retzius-sparing robot-assisted radical prostatectomy after previous trans-urethral resection of the prostate: Assessment of functional and oncological outcomes. April 5, 2023

Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022. April 4, 2023

Perceived patient burden and acceptability of MRI in comparison to PSA and ultrasound: results from the IP1-PROSTAGRAM study. April 4, 2023

Impact of piflufolastat F-18 PSMA PET imaging on clinical decision-making in prostate cancer across disease states: A retrospective review. April 4, 2023

A semi-automated software program to assess the impact of second reads in prostate MRI for equivocal lesions: results from a UK tertiary referral centre. April 4, 2023

Is Active Surveillance an Option for the Management of Men with Low-grade Prostate Cancer and a Positive Family History? Results from a Large, Single-institution Series. April 4, 2023

Transgender women with prostate cancer are under-represented in national cancer registries. April 4, 2023

Landmarks in the evolution of prostate biopsy. April 4, 2023

Neoadjuvant enoblituzumab in localized prostate cancer: a single-arm, phase 2 trial. April 4, 2023

ERLEADA® (apalutamide), First-and-Only Next-Generation Androgen Receptor Inhibitor with Once-Daily, Single-Tablet Option Now Available in the U.S. April 3, 2023

Testing the Limits of SMILES-Based De Novo Molecular Generation with Curriculum and Deep Reinforcement Learning April 3, 2023

Randomized Phase III Study of Enzalutamide Compared With Enzalutamide Plus Abiraterone for Metastatic Castration-Resistant Prostate Cancer (Alliance A031201 Trial). April 3, 2023

Early on-treatment changes in circulating tumor DNA fraction and response to enzalutamide or abiraterone in metastatic castration-resistant prostate cancer. April 3, 2023

Robotically controlled three-dimensional micro-ultrasound for prostate biopsy guidance. April 3, 2023

PARP inhibition and pharmacological ascorbate demonstrate synergy in castration-resistant prostate cancer. April 3, 2023

Page 149 of 1439